SBIR/STTR Research Award
PHOSPHOANTIBODIES AS RESEARCH TOOLS TO STUDY THE NMDAR
Award amount
$98,813Program and phase
SBIR · Phase IAward year
2002Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PHOSPHOSOLUTIONS
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
DESCRIPTION (provided by applicant): The NMDA receptor appears to play a
critical role in memory and it is widely thought to play important roles in
development and in pathological conditions such as alcoholism, and the
age-related dementias including Alzheimer?s. There is good evidence that phosphorylation of the NMDAR may be important for regulation of NMDAR function.
The specific goal of the present application will be to identify the sites on
the NMDAR that are phosphorylated and to prepare antibodies specific for those
phosphorylation sites. The ultimate goal of these studies will be to use the
antibodies to study the role of NMDAR phosphorylation in forms of plasticity
that may underlie learning as well as its role in various pathological
conditions. Thus, in this application we will test the hypothesis that specific
phosphorylation sites on the NR2 subunits of the NMDAR are subject to
LIP-related regulation in situ in the hippocampal slice. In Part 1 of the
proposal, the specific sites on the NR2 subunits of the NMDAR that are
phosphorylated will be identified. The essential milestone of this aim in Phase
I will first be mass spectrometry of NR2 fusion proteins to optimize sequence
coverage of the protein. The fusion proteins will then be phosphorylated in
vitro followed by mass spectrometry. Analysis of immunoisolated, native NR2B
and NR2B subunits will take place in Phase II. In that phase, particular
emphasis will be placed on determining the sites basally phosphorylated and
those influenced by LTP stimulation. In Part 2, phosphosite specific antibodies
for Tyr 842 in NR2A and for sties on NR2A and NR2B identified in Part 1 will be
prepared. Production of an antibody specific for phosphosite Tyr 842 will be
the principal milestone of this Part of Phase I. In Phase II phosphospecific
antibodies for sites identified in Part 1 will be prepared.
Technology keywords
Not reported